FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HERSHBERG ROBERT							2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ ADPT ]										tionship of Reporting all applicable) Director Officer (give title below)		g Per	10% Ov	vner
(Last) (First) (Middle) C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 09/15/2020														Other (specify below)	
(Street) SEATTLE WA 98102					4. If Amendment, Date of Original Filed (Month/Day/Year)											Individual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting					
(City) (State) (Zip)																	Persor	1			
		Tab	le I - No	n-Deriv	ative	e Se	curit	ies Ac	qu	ired, [	Disp	osed c	of, o	r Ber	neficia	lly O	wnec	I			
Date					2. Transaction Date (Month/Day/Year)			emed ion Date /Day/Yea	,	3. Transact Code (In 8)	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				4 and Securition Benefici Owned I		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount		(A) or (D)	Price	1	Reporte Fransact Instr. 3	tion(s)			(Instr. 4)
Common Stock 09/15/						0				M <sup>(1)</sup>		2,000	)	A	\$0.4	15	2,000			D	
Common Stock 09/15/2						0				<b>S</b> <sup>(1)</sup>		2,000	D \$42		\$42.	58	0			D	
		Т	able II -									sed of onverti				y Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemde Execution if any (Month/Da	Date,	Transaction Code (Instr.				Exp	Date Exe piration I onth/Day	Date	r) Am Sec Und Der		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Deri	rice of vative urity tr. 5)	9. Number derivative Securities Beneficiali Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate			Amount or Number of Shares						
Stock Option (Right to Buy)	\$0.45	09/15/2020			M <sup>(1)</sup>			2,000		(2)	02	2/04/2023		nmon ock	2,000	\$(	0.00	65,000	)	D	

## **Explanation of Responses:**

- 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.
- 2. The option is fully vested and exercisable.

## Remarks:

/s/ Robert Hershberg by Eric Billings, Attorney-in-Fact

09/16/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.